Montelukast Für Kinder Im Alter Von 6 Bis 14 Jahren Eurogenerics

Montelukast, the active ingredient in Montelukast Für Kinder Im Alter Von 6 Bis 14 Jahren Eurogenerics, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, exercise‑induced bronchoconstriction and allergic rhinitis in children aged 6‑14 years.

GNH USA supplies Montelukast Für Kinder Im Alter Von 6 Bis 14 Jahren Eurogenerics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage chronic airway and nasal conditions in pediatric patients.

Asthma: reduces frequency of bronchospasm and improves overall symptom control. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity. Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: transient irritation of the throat. - Sore throat: mild irritation or scratchiness. - Nausea: feeling of queasiness. - Diarrhoea: loose stools occurring occasionally.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, or angioedema requiring immediate medical attention. - Neuropsychiatric events: mood changes, agitation, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin reaction, extremely rare. - Anaphylaxis: life‑threatening systemic allergic response.

Montelukast should be used with careful clinical oversight in children.

Assess asthma control before initiation: ensure baseline symptom assessment. Monitor for neuropsychiatric events: watch for mood swings or behavioural changes. Use caution in hepatic impairment: adjust therapy if liver dysfunction is present. Do not use for acute asthma attacks: it is not a rescue medication. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Store at below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines that affect its metabolism or clinical effect.

Major Interactions (Avoid): - Phenobarbital: strong enzyme inducer that can lower montelukast plasma levels. - Rifampin: induces hepatic enzymes, potentially reducing efficacy. - Ketoconazole: potent CYP3A4 inhibitor that may increase montelukast exposure.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect; monitor INR. - Oral contraceptives: may experience reduced hormonal efficacy. - Beta‑agonists: concurrent use generally safe but monitor overall asthma control.